<DOC>
	<DOCNO>NCT00001561</DOCNO>
	<brief_summary>Both patient marrow donor treat Regimen A ; patient proceed Regimen B . The following acronym use : ABM Allogeneic Bone Marrow BU Busulfan , NSC-750 CF Leucovorin calcium , NSC-3590 CTX Cyclophosphamide , NSC-26271 G-CSF Granulocyte Colony-Stimulating Factor ( source specify ) GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor ( Hoechst/Immunex ) , NSC-613795 GVHD Graft-vs.-Host Disease Mesna Mercaptoethane sulfonate , NSC-113891 MTX Methotrexate , NSC-740 PP Unconjugated Myeloma Immunoglobulin plasma paraprotein , NSC-684150 PP-KLH Myeloma immunoglobulin plasma paraprotein vaccine , NSC-678327 , keyhole limpet hemocyanin TBI Total-Body Irradiation TSPA Thiotepa , NSC-6396 Regimen A ( Donor Patient ) : Vaccine Therapy Immunoadjuvant . PP-KLH ( individual myeloma immunoglobulin plasma paraprotein vaccine prepare recipient 's plasma paraprotein conjugate KLH ) ; PP ; GM-CSF . Regimen B ( Patient ) : Myeloablative Radiotherapy 2-Drug Combination Chemotherapy 2-Drug Combination Myeloablative Chemotherapy follow Hematopoietic Rescue Growth Factor Support GVHD Prophylaxis follow Vaccine Therapy Immunoadjuvant . TBI ; CTX/TSPA ; BU/CTX ; follow ABM ; G-CSF ; CYSP ; MTX/CF ; follow PP-KLH ; GM-CSF .</brief_summary>
	<brief_title>Active Immunization Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein Recipient Undergoing Allogeneic Bone Marrow Transplantation</brief_title>
	<detailed_description>Multiple Myeloma remain largely incurable disease current therapy . Allogeneic bone marrow transplantation provide opportunity add potential antitumor effect marrow graft high dose chemotherapy . One potential strategy enhance graft vs. tumor effect without aggravate graft vs. host disease would selectively target immune response define tumor-specific antigen . The idiotype rearrange immunoglobulin gene product myeloma serve unique tumor-specific antigen vaccine development . We test hypothesis tumor antigen-specific immunity adoptively transfer BMT recipient active immunization marrow transplant donor purify myeloma idiotype protein , conjugate carrier protein ( KLH ) administer GM-CSF immunological adjuvant . Patients age 60 HLA-matched sibling donor , minimal prior treatment , define less six month prior chemotherapy , minimal residual disease state prior allogeneic BMT , define achievement least PR , eligible . HLA match sibling donor receive series three vaccination eight week period prior bone marrow harvest . Recipients concurrently receive vaccination pre-BMT , well three booster vaccination week 12 , 16 , 24 post-BMT . Id-KLH ( 0.5 mg ) administer s.c. GM-CSF ( 250 micrograms/m ( 2 ) ) administer s.c. locally vaccine day vaccination three consecutive day follow vaccination . The objective protocol induce cellular humoral immunity marrow transplant donor recipient unique idiotype express recipient 's myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<mesh_term>Myeloma Proteins</mesh_term>
	<mesh_term>Paraproteins</mesh_term>
	<criteria>INCLUSION CRITERIA : Patient Selection : Patients IgG IgA multiple myeloma attain least PR transplantation eligible thsi protocol . Patients may receive 34 course VAD , high dose cyclophosphamide one autologous transplant enter study . All previous therapy must complete least 2 week prior study entry . Patients recover hematologic nonhematologic toxicity previous therapy . Steroid must discontinue least two week prior vaccination . Only patient le 60 year eligible protocol . Patients must meet following criterion : A. Karnofsky performance status great equal 70 percent . B . Life expectancy great 8 week absence coexist medical problem would significantly increase risk transplant procedure judgment bone marrow transplant attend physician ( e.g. , MUGA leave ventricular ejection fraction great 50 % DLCO great thant 50 % expect value correct Hb ) . Creatinine le 2x normal rise least 24 week transplantation . If creatinine elevate , creatinine clearance must great 40 ml/min . Direct bilirubin le 2 mg/dl , SGOT le 4x top normal , none parameter increase , least 24 week transplantation . Patients must HIVnegative , HBsAg , Hepatitis C antibody Negative . Not pregnant lactating . Patients childbearing potential must use effective method contraception . Mprotein concentration harvest plasma must great 90 percent total Ig corresponding isotype . Patients must great equal 18 year old . Donor criterion : Any consent healthy individual fulfills donor criterion consider marrow donation . HLAidentical sibling donor . HLA , A B DR phenotypically identical family donor . HIV , hepatitis B C seropositive . Complete blood count , platelet , PT , PTT within normal limit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Idiotype-Specific Immunity</keyword>
	<keyword>Immune Transfer</keyword>
	<keyword>Myeloma Immunoglobulin</keyword>
</DOC>